CurrentAetnaPolicy 0491

Coronary Artery Brachytherapy and Other Adjuncts to Coronary Interventions

Defines Aetna's medical necessity and investigational determinations for intracoronary brachytherapy and adjunctive therapies (e.g., abciximab, intravascular lithotripsy) relevant to percutaneous coronary interventions for providers and claims reviewers.

Policy Summary

PayerAetna

PolicyCoronary Artery Brachytherapy and Other Adjuncts to Coronary Interventions

Policy CodePolicy 0491

Change TypeRoutine review

Effective DateJan 8, 2002

Next Review DateMay 9, 2024

Key ActionObtain and document clinical indication and lesion imaging when seeking prior authorization for intracoronary brachytherapy or IVL.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

~105references

2,065AIDA STEMI RCT patients

92.2%Disrupt CAD 30-day freedom from MACE

93%IVL pooled procedural success

290DES ISR single-center series

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medically Necessary

Medically necessary interventions

ALL of the following

Coronary artery brachytherapy (intra-coronary radiation) is considered medically necessary as an adjunctive treatment during a second angioplasty/stent placement for localized in-stent restenosis within a previously placed bare metal stent (BMS).
Abciximab (ReoPro) is considered medically necessary as an adjunctive treatment for persons undergoing percutaneous coronary angioplasty and/or stent placement when used in accordance with FDA labeling and appropriate peri-procedural antiplatelet/anticoagulant therapy.

Notes

FDA labeling contraindications must be observed (e.g., patients who are not candidates for blood-thinning drugs or antiplatelet therapy should not receive coronary brachytherapy or certain adjunctive agents).
Routine use of intracoronary abciximab cannot be universally recommended; consider intracoronary administration in selected high-risk patients based on available randomized trial and meta-analysis data.

Experimental / Investigational

Experimental / Investigational — interventions considered not established

ALL of the following

Coronary artery brachytherapy for use with drug-eluting stents (DES), for primary prevention of restenosis (de novo lesions), and for all indications other than treatment of in-stent restenosis of bare metal stents is considered experimental and investigational due to insufficient evidence of long-term safety and effectiveness.
Abciximab is considered experimental and investigational for the following indications because randomized controlled trial evidence is insufficient to establish safety or effectiveness: acute ischemic stroke; acute limb ischemia; acute myocardial infarction without percutaneous intervention; cardiac complications of Kawasaki disease; saphenous vein graft interventions; stenting of superficial femoral occlusive disease; thromboembolic complications during cerebral aneurysm coiling; thrombus resolution during intracranial bypass surgery; and abciximab/heparin therapy for LVAD implantation in patients with heparin-induced thrombocytopenia.
Intravascular shockwave lithotripsy (IVL) for treatment of coronary artery plaques is considered experimental and investigational where evidence is insufficient to support effectiveness for some FDA-indicated uses or where randomized comparative data versus alternative plaque-modifying strategies are lacking.

Adjunctive abciximab (IC vs IV) — evidence statements

Adjunctive intracoronary (IC) versus intravenous (IV) abciximab — evidence summary

ALL of the following

Randomized trials and meta-analyses show IC abciximab improves myocardial perfusion measures compared with IV administration but do not consistently demonstrate mortality benefit across unselected STEMI populations.
Large randomized trials (e.g., AIDA STEMI) found no significant difference in composite clinical endpoints between IC and IV abciximab at 90 days; other meta-analyses suggest potential benefit in high-risk subgroups.
Given inconsistent clinical outcome benefits and variability by patient risk profile, routine intracoronary administration is not universally recommended; it may be considered in selected high-risk patients.

Operational note

Clinicians should follow FDA labeling, local protocols, and assess bleeding risk and candidacy for antiplatelet therapy prior to abciximab use.

Non-coronary and special-case uses — evidence statements

ALL of the following

Evidence for abciximab in non-coronary settings (e.g., acute limb ischemia, acute ischemic stroke, thromboembolic complications during aneurysm coiling, intracranial bypass surgery) is limited to small series, case reports, or retrospective analyses; safety and effectiveness are not established by randomized trials.
Use of abciximab in these settings should be considered experimental and investigational and is not covered except within the indications supported by high-quality evidence.

Special-case: ICBT for DES ISR

Retrospective series suggest intracoronary brachytherapy (ICBT) can be effective and technically successful for recurrent in-stent restenosis of drug-eluting stents, but prospective comparative data are limited; clinical judgment and consideration of alternative therapies are advised.

ICBT for drug-eluting stent in-stent restenosis

Intracoronary brachytherapy for DES in-stent restenosis — evidence

ALL of the following

Retrospective analyses report reasonable technical success and acceptable short- and mid-term outcomes for ICBT in DES ISR in complex lesions; however, higher-quality prospective data are needed to define effectiveness and optimal patient selection.

Clinical note

When considering ICBT for DES ISR, clinicians should weigh available institutional experience, lesion complexity, prior therapies, and patient candidacy for repeat interventions.

No coverage criteria specified

ALL of the following

This policy section does not specify additional coverage criteria beyond the medically necessary and investigational determinations listed above. Payers and providers should refer to the plan's benefit documents and prior authorization requirements for any service-level coverage decisions and to FDA labeling for device- or drug-specific contraindications and usage recommendations.
Where evidence is insufficient or interventions are designated investigational, prior authorization should be denied or referred for medical review in accordance with plan procedures.

Provider action

Verify member benefits and obtain prior authorization when indicated before performing intracoronary brachytherapy, use of abciximab, or intravascular lithotripsy.
Document indication, prior therapies, lesion characteristics, and rationale for use when pursuing treatments considered investigational to support case review.

IVL — Clinical use considerations

Intravascular lithotripsy (IVL) — clinical use considerations

ALL of the following

Single-arm Disrupt CAD studies and observational series demonstrate high procedural and angiographic success for IVL in severely calcified de-novo coronary lesions, but randomized comparative trials versus atherectomy or modified balloons are lacking.
Because evidence is primarily from single-arm studies, IVL as routine first-line therapy lacks randomized comparative evidence; selection should consider lesion anatomy and alternative plaque modification strategies.

Trial exclusions

Clinical trials of IVL excluded extremely tortuous vessels, true bifurcation lesions, unprotected left main, and ostial lesions; extrapolation of trial results to these subgroups is limited.

PzF stents — Clinical use considerations

Polyzene-F (PzF) stents — clinical use considerations

ALL of the following

Single-arm studies of PzF nanocoated coronary stents report favorable short- and mid-term safety and effectiveness, including low rates of stent thrombosis; however, randomized comparative data are limited.
Evidence base is limited by small sample sizes and lack of RCTs; clinicians should consider these factors when selecting stent platforms.

Follow-up

Long-term outcomes beyond 5 years require further study; monitor patients per standard clinical practice and device labeling.

Coding — CPT, HCPCS, ICD-10

Covered CPT codesCPTCovered

92974

Transcatheter placement of radiation delivery device for subsequent coronary intravascular brachytherapy (List separately in addition to code for primary procedure)

Not covered CPT codesCPTNot Covered

61624	Transcatheter occlusion or embolization, percutaneous, any method; central nervous system [intracranial, spinal cord]
92972	Percutaneous transluminal coronary lithotripsy (List separately in addition to code for primary procedure)

Other related CPT codesCPT

33510-33516	Coronary artery bypass, vein only; 1-6 or more coronary venous grafts
33979	Insertion of ventricular assist device, implantable intracorporeal, single ventricle
96365-96368, 96374-96379	Intravenous infusion and push

Covered HCPCS codesHCPCSCovered

C7533	Percutaneous transluminal coronary angioplasty, single major coronary artery or branch with transcatheter placement of radiation delivery device for subsequent coronary intravascular brachytherapy
J0130	Injection abciximab, 10 mg [except for the management of acute myocardial infarction without percutaneous coronary intervention]
Q3001	Radioelements for brachytherapy, any type, each

Not covered HCPCS codesHCPCSNot Covered

C1761

Catheter, transluminal intravascular lithotripsy, coronary

Other related HCPCS codesHCPCS

C1874-C1875

Stent, coated/covered, with or without delivery system

Covered ICD-10 codesICD-10Covered

I20.0-I25.3	Ischemic heart diseases
I25.42-I25.9	Ischemic heart diseases
T82.211+ - T82.218+	Mechanical complication due to coronary bypass graft
T82.817+ - T82.897+	Other specified complications of other cardiac devices, implants and grafts
T82.9xx+	Other specified complications of other cardiac devices, implants and grafts
Z95.1	Presence of aortocoronary bypass graft
Z95.5	Presence of coronary angioplasty implant and graft
Z98.61	Coronary angioplasty status

Not covered ICD-10 codesICD-10Not Covered

D75.821-D75.829	Heparin-induced thrombocytopenia
I25.41	Coronary artery aneurysm
I63.00-I66.9	Occlusion and stenosis of cerebral and precerebral arteries
I74.3	Embolism and thrombosis of arteries of the lower extremities
I99.9	Unspecified disorder of circulatory system [acute limb ischemia]
M30.03	Mucocutaneous lymph node syndrome

Provider Actions — Prior Authorization, Documentation, Denial Risk

Prior Authorization

Prior authorization may be required for intracoronary brachytherapy codes

Prior authorization may be required when billing for intracoronary brachytherapy procedures or related HCPCS/CPT codes (e.g., 92974, C7533, J0130, Q3001) if the service is being claimed as medically necessary under the policy selection criteria.

Codes referenced in the policy: CPT 92974; HCPCS C7533, J0130, Q3001.
Authorization expected when claiming medical-necessity indications listed in the policy.

Prior Authorization

No prior authorization specified in this section

This excerpt does not specify any explicit prior authorization requirements or particular billing codes for the sections referenced.

Prior Authorization

No prior authorization stated in IVL discussion

No prior authorization requirements or billing code authorizations are specified in the document excerpt for the topics covered in these chunks.

Prior Authorization

Prior authorization likely required for IVL — document need for conventional technique consideration

Because evidence for IVL is primarily from single‑arm observational studies and registries, prior authorization may require documentation that conventional techniques were considered or that the lesion is severely calcified before approving IVL.

Policy notes that available IVL evidence is largely nonrandomized and registry-based.
Documentation that the lesion is severely calcified or that conventional methods failed may be requested.

Prior Authorization

Policy history noted; no explicit prior‑auth rules in history

The policy includes administrative history (last and next review dates) but does not state specific prior authorization requirements in these policy‑history chunks.

Note

No provider action specified

No explicit provider action is defined in these chunks for the referenced section.

Step Therapy

No step therapy rules provided

No step‑therapy rules are provided in the policy extract.

Step Therapy

No explicit step therapy; IVL described as primary/secondary/tertiary in reports

The extract contains no explicit step‑therapy requirements; clinical reports describe IVL as being used as primary, secondary (after non‑compliant balloon failure), or tertiary (for under‑expanded stents) strategies.

Umapathy et al described primary, secondary, and tertiary IVL use groups (primary IVL; secondary after NC‑balloon failure; tertiary for under‑expanded stents).

Note

Position in therapy unclear—no RCTs comparing IVL with atherectomy/cutting balloons

The policy notes there are no randomized head‑to‑head trials comparing IVL with atherectomy or cutting balloons, indicating uncertainty about IVL’s position relative to other plaque‑modification techniques.

Meta-analysis and registry summaries state absence of randomized comparisons between IVL and atherectomy or cutting balloons.

Step Therapy

No sequencing or step‑therapy requirements specified

No step‑therapy or formal sequencing requirements are specified in this excerpt; the cited literature addresses a variety of therapies without prescribing an order for use.

Documentation Required

Document clinical indication: adjunctive brachytherapy for repeat angioplasty/stent for localized ISR

Documentation should support that intracoronary brachytherapy is being used as adjunctive treatment during a second angioplasty/stent placement for localized in‑stent restenosis of a previously placed bare metal stent, consistent with the policy’s medically necessary indication.

Indication must align with policy: adjunctive therapy during repeat angioplasty/stent for in‑stent restenosis of a prior BMS.
Policy states FDA-approved devices are limited to previously implanted stents that have re‑stenosed.

Documentation Required

Document route and clinical context for abciximab (IC vs IV) when used

Randomized trials and meta‑analyses comparing intracoronary versus intravenous abciximab are cited; documentation of the route of administration (IC vs IV) and the clinical context (e.g., STEMI, primary PCI) may be relevant when justifying use.

AIDA STEMI randomized trial (IC vs IV) and meta‑analyses are referenced.
Policy notes IC use may improve myocardial perfusion but not consistently clinical outcomes; route should be documented.

Documentation Required

No operational documentation requirements specified

No specific provider actions or operational documentation requirements are stated in these chunks.

Documentation Required

Document imaging and lesion characteristics—studies often used angiography not routine IVUS/OCT

Many IVL studies relied on angiographic assessment rather than routine intracoronary imaging (IVUS/OCT); documentation of lesion characteristics and any imaging performed may be expected to support IVL use.

Registries had limited intracoronary imaging due to reimbursement or study design.
Severity of calcification and outcomes were often evaluated angiographically rather than with IVUS/OCT.

Documentation Required

Policy history referenced; no checklist or required forms provided

Policy history and administrative pages are referenced in the document, but these chunks do not provide a concrete documentation checklist or required prior‑authorization forms.

Denial Risk

Denial risk if billing codes listed as not covered are used for excluded indications

Claims for CPT/HCPCS/ICD‑10 codes listed as 'not covered' in the bulletin (for example C1761, 92972) may be denied when submitted for excluded indications.

HCPCS C1761 and CPT 92972 are listed as not covered for indications in this bulletin.
Providers should verify code coverage before billing to avoid denials.

Denial Risk

No explicit denial triggers stated in this excerpt

No explicit payer denial triggers or prior authorization directives are stated in these chunks.

Note

No provider actions stated

This section contains no specific provider actions to take.

Denial Risk

Evidence limitations for IVL may affect coverage decisions

The policy highlights limitations in the evidence base for IVL—lack of randomized data and limited intracoronary imaging in registries—which may influence coverage determinations and prior‑authorization decisions.

Registries were nonrandomized and had limited intracoronary imaging.
Policy explicitly states insufficient randomized comparative evidence as an evidence gap.

Note

No further provider actions in policy history chunks

No additional provider actions are specified in these chunks.

Definitions and Key Terms

In-stent re-stenosis definition

DefinitionRecurrence of coronary stenosis within the site of a previously implanted stent.

Typical frequencyOccurs in approximately 20–30% of patients with prior stent implantation.

Clinical implicationWhen restenosis occurs within a stent, treatment options include pharmacotherapy and/or repeat angioplasty followed by consideration of brachytherapy.

Intracoronary brachytherapy definition

DefinitionDelivery of localized gamma or beta radiation via a catheter to the treated coronary segment to inhibit cellular proliferation and reduce restenosis.

Delivery methodA special catheter is passed into the coronary arteries and across the target area; once the area is bracketed, radiation is applied.

Radiation types & devicesTwo radiation types used are gamma (Cordis Checkmate System) and beta (Novoste Beta‑Cath System); FDA approvals are limited to treatment of in‑stent restenosis in previously implanted stents.

IC abciximab definition

DefinitionIntracoronary (IC) abciximab is intracoronary bolus administration of abciximab delivered at or near the infarct lesion site during PCI, typically followed by an intravenous infusion.

Dosing context (trial example)AIDA STEMI administered an IC or IV bolus (0.25 mg/kg) during PCI with a subsequent 12‑hour IV infusion (0.125 μg/kg/min, max 10 μg/min).

Evidence summaryRandomized trials and meta-analyses show IC administration improves myocardial perfusion versus IV, but consistent mortality benefit is not demonstrated; IC may be considered in high‑risk patients rather than used routinely.

ICBT shorthand definition

ShorthandICBT = Intracoronary brachytherapy — local radiation therapy applied within coronary arteries to treat in‑stent restenosis.

Primary useUsed as adjunctive treatment during repeat angioplasty/stent placement for localized in‑stent restenosis of previously implanted stents.

Device constraintsFDA‑approved devices (e.g., Checkmate, Beta‑Cath) are indicated for previously implanted stents that have re‑stenosed and for specified vessel diameters and lesion lengths.

Intravascular lithotripsy (IVL) definition

DefinitionIntravascular lithotripsy (IVL) is a balloon‑based system that delivers sonic/ultrasonic pressure waves via a catheter balloon to fracture arterial calcification and increase vessel compliance prior to stent implantation.

MechanismLithotripsy is generated by vaporizing fluid to create expanding bubbles that produce pressure waves interacting with arterial calcium to facilitate low‑pressure balloon dilatation.

Regulatory noteFDA approved the Shockwave IVL System (Shockwave C2 coronary IVL catheter) in February 2021 for lithotripsy‑enabled low‑pressure balloon dilatation of severely calcified de‑novo coronary arteries prior to stenting; evidence for effectiveness remains limited.

Glycoprotein IIb/IIIa inhibitors (GPI) definition

DefinitionGlycoprotein IIb/IIIa inhibitors (GPI) are a class of platelet aggregation inhibitors (examples: abciximab, tirofiban, eptifibatide) used as adjunctive antithrombotic therapy in PCI and STEMI to reduce ischemic complications.

Clinical trade name exampleAbciximab (ReoPro) is a GPI used as adjunctive treatment during percutaneous angioplasty/stent placement.

Benefit vs riskRoutine GPI use in STEMI has been associated with reductions in mortality and ischemic events in older trials but increases major and minor bleeding; contemporary data with newer antiplatelet agents are limited.

Intravascular lithotripsy (IVL) alternate definition

Alternate phrasingIVL: a technique delivering sonic pressure waves via a balloon catheter that fracture arterial calcification to increase vessel compliance prior to stent implantation.

Clinical roleUsed for lesion preparation in severely calcified coronary plaques to facilitate stent delivery and expansion, with observational evidence showing high procedural and angiographic success.

Evidence gapNo randomized trials directly comparing IVL with atherectomy or cutting balloons were reported in the provided text; available evidence is primarily single‑arm registries and observational studies.

Polyzene‑F (PzF) nanocoated stent definition

DefinitionPolyzene‑F (PzF) nanocoated stent is a coronary stent with a Polyzene‑F nanocoating (COBRA/CATANIA systems) designed to reduce stent thrombosis and potentially allow shorter or less intensive antiplatelet therapy.

Clinical outcomesSingle‑arm studies and a pooled meta‑analysis reported low stent thrombosis rates (ST ≈ 0.4%) and pooled target vessel failure (TVF ≈ 8.9%), with favorable safety and effectiveness through 5 years in cohort data.

LimitationsEvidence derives largely from nonrandomized studies and single‑arm meta‑analyses with relatively small sample sizes; lack of RCT comparisons noted.

FDA approvals/devices references

FDA approvals (brachytherapy devices)Cordis Checkmate System (gamma) and Novoste Beta‑Cath System (beta) received FDA premarket approvals for treatment of in‑stent restenosis in previously implanted stents (see FDA PMAs cited).

Abciximab prescribing informationFDA prescribing information for ReoPro (abciximab) is referenced for intravenous administration and clinical context.

IVL regulatory statusFDA approved the Shockwave IVL System (Shockwave C2 coronary IVL catheter) in February 2021 for lithotripsy‑enabled low‑pressure balloon dilatation of severely calcified de‑novo coronary arteries prior to stenting (see IVL discussion).

OpenPayer

Coronary Artery Brachytherapy and Other Adjuncts to Coronary Interventions

Coverage Criteria — Medically Necessary and Investigational Determinations

Coding — CPT, HCPCS, ICD-10

Provider Actions — Prior Authorization, Documentation, Denial Risk

Background — Mechanisms and Historical Context

Definitions and Key Terms

Revision History and Policy Dates